Dear Doctor, Dear Sir/Madam,

Asthma is a chronic inflammatory disease of the airways. Approximately 5-10% of asthma patients have a severe form of the disease. Both severe asthma and asthma that is difficult to treat, significantly affect the patient's quality of life and medical management.

We invite you to participate in an international survey aimed at determining the place of anticholinergic drugs (LAMA) in the treatment of asthma. The survey has been designed in the form of electronic questionnaires and will be conducted in Poland, Sweden, Finland, Slovenia, Austria, and Greece until April 30, 2023.

After the project is completed, a report containing a statistical analysis of the collected data will be prepared.

Support for conducting the survey - Chiesi company employees (Medical Science Liaison team). Methodology development, research tool creation, and overall results analysis - Biostat Sp. z o.o.

Thank you very much for participating in the survey!

Safety monitoring of pharmacotherapy

In accordance with the Act of September 6, 2001 on Pharmaceutical Law, every adverse drug reaction must be reported immediately to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products or to the appropriate responsible entity.

In the event of any adverse reaction, as well as in cases of particular concern (overdose, improper use, abuse, medical errors, use inconsistent with the recommendations in the product characteristics, occupational exposure, lack of efficacy, drug interactions, and use during pregnancy and lactation) related to the use of Chiesi medicinal products, please send a report to the following email address: [email protected].